RNA
Avidity Biosciences is a biotechnology company focused on developing a new class of targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates (AOC™) platform. Starting with a muscle disease franchise, the company aims to address root causes of disease and expand its pipeline to additional tissues and therapeutic areas. Headquartered in San Diego, California, the organization emphasizes delivering RNA-based therapies to previously inaccessible cells and tissues. Their programs target diseases such as myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy, advancing toward broad patient impact.